Absci Corp (ABSI) presents a structurally negative liquidation posture, consistent with a pre-revenue clinical-stage AI drug discovery company funded by equity drawdowns. As of March 31, 2026, total assets of $195.6M are dominated by cash equivalents ($8.6M), marketable securities ($121.9M current + $4.8M noncurrent), and intangible assets ($40.8M). Under liquidation haircuts, cash recovers at par (~$8.6M), marketable securities (US government and investment-grade instruments typical for biotech treasuries) recover near par (~$121-123M combined), and intangibles receive zero recovery — eliminating $40.8M of book value. PP&E of $18.8M applies a 50-70% haircut (lab equipment, single-facility concentration), yielding roughly $9-13M. Operating lease ROU asset ($2.6M) receives no liquidation credit while the associated liabilities ($4.0M combined current and noncurrent) remain at face value. Restricted cash ($1.1M noncurrent) recovers at par. Prepaid and other current assets ($6.3M) recover at roughly 50-60%, yielding ~$3-4M. Total liquidation asset recovery is estimated at approximately $145-150M against total liabilities of $23.6M at face value, implying a rough equity recovery of $121-126M against book stockholders' equity of $172.0M — a haircut of roughly $46-51M, driven primarily by intangibles write-off ($40.8M) and PP&E discount. The MFFAIS CLV/LLV/OLV values of approximately -$13.5M appear to reflect a different methodology (possibly including off-balance-sheet commitments or more aggressive asset haircuts not fully visible in the XBRL). The company burned $26.3M in operating cash in Q1 2026 and raised $8.0M via ATM equity issuance. The accumulated deficit stands at $654.4M. The largest liquidation risk factor is runway: at the current burn rate, the $130.7M in marketable securities plus $8.6M cash provides roughly 4-5 quarters of runway absent additional fundraising. No long-term debt of note; equipment notes payable ($0.4M current) are de minimis. The prior filing (10-K for year ended December 31, 2025) does not provide a directly comparable Q1 2025 balance sheet in the provided text, but the annual filing disclosed intangibles and goodwill structures that remain consistent. Material change from prior annual period: the company transitioned from a platform-services model toward internally developed clinical programs (ABS-201 in Phase 1 in Australia), increasing forward cash commitments and R&D burn. Filing discusses future clinical supply commitments and CRO obligations in MD&A but does not separately tag committed expenditure amounts in XBRL.
▼ Community Notes